Pharmaceuticals company SMS Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations in Q4FY24 was Rs 248.20 crore, up 1% YoY, driven by strong demand for key APIs. PAT for Q4FY25 stood at Rs 20.31, up 18% In Q4FY25, gross margins improved to 30%, an increase of 444 bps year-on-year, driven by backward integration, product mix, and a stable pricing environment. EBITDA margins for Q4FY25 stood at 16%, up 277 bps year-on-year, and PAT margins rose to 8%. FY25 Financial Highlights: For FY25, revenue from operations reached Rs 782.75 crore, reflecting a 10% YoY growth. We witnessed healthy growth in our high-value product portfolio. PAT for FY25 stood at Rs 69.14, up by 39% For FY25, gross margin increased to 33%, EBITDA margin to 18%, and PAT margin improved to 9%. The Board has recommended a final dividend of Rs 0.4 (40%) per equity share with a face value of Rs 1 each for FY25. New Capex of Rs 250 crore to expand capacity for new products and CMO busines Commenting on the performance, P. Vamsi Krishna, Executive Director, stated: We concluded FY25 on a strong note with 39% PAT growth, driven by volume growth and margin expansion. This was made possible by the disciplined execution of our strategy over the past four years: strengthening and diversifying our product portfolio, driving operational efficiencies, and achieving cost leadership through backward integration and scale. A key milestone was the successful ramp-up of ibuprofen, positioning us among India’s leading producers. We also onboarded several large customers across our API portfolio, further strengthening long-term revenue growth. With the backward integration project completed, key APIs at the take-off stage, and a new Capex plan underway, we are entering FY26 with strong momentum and greater earnings visibility. We are also building a robust pipeline of new molecules to drive long-term growth. Result PDF
Pharmaceuticals company SMS Pharmaceuticals announced Q3FY25 results Revenue from operations in Q3FY24 was Rs 173.35 crore, up 7% YoY, driven by strong demand. In Q3FY25, gross margins improved to 39%, up 729bps YoY and 870bps sequentially. EBITDA margins for Q3FY25 stood at 19%, up 120bps YoY and 316bps sequentially. PAT rose to Rs 18.24 crore, up 341bps YoY and 336bps sequentially, with PAT margin expanding to 11%. P. Vamsi Krishna, Executive Director, said: “We continued to see healthy volume demand for our products, supported by notable client wins across key APIs an encouraging sign for future growth. While we are navigating pricing pressures, our focus on profitability has kept margins strong and steady. Looking ahead, we expect to end the year on a strong note. The second phase of our backward integration project, set to begin commercial production in March 2025, will drive margin expansion from FY26 onwards. Our CMO business is also set to take off and contribute to our performance. Additionally, our capacity expansion remains on track, enabling us to scale volumes across our key APIs.” Result PDF
Conference Call with SMS Pharmaceuticals Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.